These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27556126)

  • 21. Early hepatocellular carcinomas showing isointensity or hyperintensity in gadoxetic acid-enhanced, hepatocyte-phase magnetic resonance images.
    Chen N; Motosugi U; Sano K; Ichikawa T; Nakano M; Morisaka H; Ichikawa S; Matsuda M; Fujii H; Enomoto N; Araki T
    J Comput Assist Tomogr; 2013; 37(3):466-9. PubMed ID: 23674023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocyte-phase imaging.
    Chou CT; Chen YL; Su WW; Wu HK; Chen RC
    J Magn Reson Imaging; 2010 Oct; 32(4):895-902. PubMed ID: 20882620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging.
    Ito K
    Eur J Radiol; 2006 May; 58(2):186-99. PubMed ID: 16413154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Education and imaging. Hepatobiliary and Pancreatic: Detection of early hepatocellular carcinoma by enhanced magnetic resonance imaging.
    Eso Y; Marusawa H; Osaki Y
    J Gastroenterol Hepatol; 2012 Feb; 27(2):416. PubMed ID: 22260287
    [No Abstract]   [Full Text] [Related]  

  • 25. Liver-specific magnetic resonance contrast medium in the evaluation of chronic liver disease.
    Reis MA; Baroni RH
    Einstein (Sao Paulo); 2015; 13(2):326-9. PubMed ID: 26154554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [MR contrast agent: resovist (SH U 555A)].
    Nakajima H; Ichikawa T
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():328-32. PubMed ID: 11761967
    [No Abstract]   [Full Text] [Related]  

  • 27. [Indications of clinical uses of contrast agents for MR imaging of liver].
    Chen F; Ni YC
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):299-300. PubMed ID: 15854502
    [No Abstract]   [Full Text] [Related]  

  • 28. Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease.
    Motosugi U; Ichikawa T; Sano K; Sou H; Onohara K; Muhi A; Kitamura T; Amemiya F; Enomoto N; Matsuda M; Asakawa M; Fujii H; Araki T
    Invest Radiol; 2011 Feb; 46(2):141-5. PubMed ID: 21139506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR.
    Kagawa Y; Okada M; Kumano S; Katsube T; Imaoka I; Tanigawa N; Ishii K; Kudo M; Murakami T
    J Magn Reson Imaging; 2011 Apr; 33(4):864-72. PubMed ID: 21448951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [High resolution MR imaging of small hepatocellular carcinoma using breathhold technique].
    Imai Y; Higuchi N
    Nihon Rinsho; 1991 Aug; 49(8):1832-6. PubMed ID: 1664889
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatocellular carcinoma: diagnostic criteria by imaging techniques.
    Ronot M; Vilgrain V
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):795-812. PubMed ID: 25260309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guest editor's introduction: hepatocellular nodules in liver cirrhosis: imaging update 2011.
    Choi BI
    Abdom Imaging; 2011 Jun; 36(3):230-1. PubMed ID: 21267564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical magnetic resonance imaging findings in hepatocellular carcinoma.
    Roumanis PS; Bhargava P; Kimia Aubin G; Choi JI; Demirjian AN; Thayer DA; Lall C
    Curr Probl Diagn Radiol; 2015; 44(3):237-45. PubMed ID: 25823550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.
    Motosugi U; Bannas P; Sano K; Reeder SB
    J Magn Reson Imaging; 2015 Feb; 41(2):251-65. PubMed ID: 25104398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidetector row CT and MR imaging in diagnosing hepatocellular carcinoma.
    Murakami T; Hori M; Kim T; Kawata S; Abe H; Nakamura H
    Intervirology; 2004; 47(3-5):209-26. PubMed ID: 15383731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of breath-hold multislice dynamic MRI of hepatocellular carcinomas].
    Itoh K; Honjo K; Honma Y; Hatanaka M; Choji T; Uchisako H; Kuramitsu T; Tanaka N; Nakaki H; Matsumoto T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1992 Mar; 52(3):399-401. PubMed ID: 1315953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hepatocyte targeted MR contrast agent--Gd-BOPTA(E-7155)].
    Kuwatsuru R; Katayama H
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():323-7. PubMed ID: 11761966
    [No Abstract]   [Full Text] [Related]  

  • 39. Contrast enhanced ultrasound and magnetic resonance imaging for hepatoma diagnosis.
    Wiwanitkit V
    Med Ultrason; 2014 Mar; 16(1):80. PubMed ID: 24567932
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatobiliary MRI: current concepts and controversies.
    Glockner JF
    J Magn Reson Imaging; 2007 Apr; 25(4):681-95. PubMed ID: 17352396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.